About Thalia Therapeutics

Thalia Therapeutics is a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease.

In its first initiative under this strategy, Thalia Therapeutics is advancing a novel long-duration, dual-acting siRNA programme targeting PCSK9 and lipoprotein(a) [Lp(a)], two genetically driven and clinically validated risk factors for cardiovascular disease.

Cardiovascular disease remains among the leading causes of global morbidity and mortality. Elevated levels of PCSK9 and genetically determined Lp(a) are strongly associated with increased cardiovascular risk, and effective, durable reduction of both targets has the potential to significantly reduce cardiovascular events across global populations.

By addressing these key drivers of disease, Thalia Therapeutics aims to deliver therapies that improve patient longevity and quality of life while helping to reduce the long-term burden and cost of cardiovascular disease on healthcare systems worldwide.

In parallel to this new strategy, Thalia Therapeutics continues to develop its proprietary Nuvec™ technology for the delivery of nucleic acid therapeutics.

The Company is listed on the AIM market of the London Stock Exchange and is headquartered in London.